/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

InterCure Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.29 -0.0076(-0.76%) INCR at 04 Dec 2025 04:35 PM Drug Manufacturers - Specialty & Generic
Lowest Today 1.3
Highest Today 1.3
Today’s Open 1.3
Prev. Close 1.32
52 Week High 1.79
52 Week Low 1.22
Day’s Range: Low 1.3 High 1.3
52-Week Range: Low 1.22 High 1.79
1 day return -
1 Week return -
1 month return -
3 month return -15.82
6 month return -14.19
1 year return -9.52
3 year return -72.0
5 year return -
10 year return -

Institutional Holdings

Fidelity Nasdaq Composite Index 0.04

Dimensional International Small Cap ETF 0.03

Dimensional International Core Eq 2 ETF 0.02

Dimensional World ex US Core Eq 2 ETF 0.00

Market Status

Fundamentals

Market Cap 72.18 M

PB Ratio 0.5549

PE Ratio 0.0

Enterprise Value 112.21 M

Total Assets 762.57 M

Volume 7066

Company Financials

Annual Revenue FY23:355553000 355.6M, FY22:388684000 388.7M, FY21:219677000 219.7M, FY20:65035000 65.0M, FY19:8926000 8.9M

Annual Profit FY23:105095000 105.1M, FY22:155083000 155.1M, FY21:91131000 91.1M, FY20:31975000 32.0M, FY19:1479000 1.5M

Annual Net worth FY23:-61959000 -62.0M, FY22:44819000 44.8M, FY21:7296000 7.3M, FY20:-36040000 -36.0M, FY19:-2996000 -3.0M

Quarterly Revenue Q1/2025:56556000 56.6M, Q2/2024:62866500 62.9M, Q1/2024:62866500 62.9M, Q2/2023:102439000 102.4M, Q1/2023:105606000 105.6M

Quarterly Profit Q1/2025:195500 0.2M, Q2/2024:20830000 20.8M, Q1/2024:20830000 20.8M, Q2/2023:32641000 32.6M, Q1/2023:25860000 25.9M

Quarterly Net worth Q1/2025:-34614000 -34.6M, Q2/2024:716500 0.7M, Q1/2024:716500 0.7M, Q2/2023:4883000 4.9M, Q1/2023:5266000 5.3M

Fund house & investment objective

Company Information InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company has a strategic alliance with Cannasoul R&D Ltd. for the research, development, and commercialization of evidence-based cannabis therapeutics. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Organisation Drug Manufacturers - Specialty & Generic

Employees 320

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Alexander Rabinovich

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow